All Stories

  1. Evaluation of rectal swab compared with bulk stool sampling for detection of Cryptosporidium infection by light-emitting diode auramine-phenol microscopy in young children with diarrhoea
  2. Visited India? Metronidazole may not cure your Giardia infection
  3. Diversity of domestic and imported assemblages of Giardia in Norway and multi-locus sequence typing of domestic assemblage A isolates
  4. Cryptosporidium infection and associated factors among diarrheic children under five years of age in Eastern Ethiopia
  5. Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection
  6. Development of Protective Immunity Against Diarrheal Disease in Early Years of Life
  7. Characterization of Early Lesions of Human Post-Primary Tuberculosis and Its Progression to Necrosis Using Archival Material of the Pre-Antibiotic Era
  8. Transitioning from microscopy to PCR for protozoa in Norway – Impact on detection of protozoa and helminths: A register study
  9. Inflammation, the kynurenines, and mucosal injury during human experimental enterotoxigenic Escherichia coli infection
  10. Colicins and T6SS-based competition systems enhance enterotoxigenic E. coli (ETEC) competitiveness
  11. The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops
  12. Reduced Plasma Guanylin Levels Following Enterotoxigenic Escherichia coli-Induced Diarrhea
  13. Dynamics of circulating lymphocytes responding to human experimental enterotoxigenic Escherichia coli infection
  14. Genetic diversity in the metronidazole metabolism genes nitroreductases and pyruvate ferredoxin oxidoreductases in susceptible and refractory clinical samples of Giardia lamblia
  15. Highly contiguous genomes of human clinical isolates of Giardia duodenalis reveal assemblage- and sub-assemblage-specific presence–absence variation in protein-coding genes
  16. Strong Association between Diarrhea and Concentration of Enterotoxigenic Escherichia coli Strain TW10722 in Stools of Experimentally Infected Volunteers
  17. Oocyst Shedding Dynamics in Children with Cryptosporidiosis: a Prospective Clinical Case Series in Ethiopia
  18. A comparison of risk factors for cryptosporidiosis and non-cryptosporidiosis diarrhoea: A case-case-control study in Ethiopian children
  19. Conserved metabolic enzymes as vaccine antigens for giardiasis
  20. Transition to PCR diagnosis of cryptosporidiosis and giardiasis in the Norwegian healthcare system: could the increase in reported cases be due to higher sensitivity or a change in the testing algorithm?
  21. No difference in serum levels of B‐cell activating receptor and antibodies against cytolethal distending toxin B and flagellin in post‐infectious irritable bowel syndrome and chronic fatigue syndrome after Giardia infection
  22. Characterization of Glycosylation-Specific Systemic and Mucosal IgA Antibody Responses to Escherichia coli Mucinase YghJ (SslE)
  23. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders
  24. A site assessment tool for inpatient controlled human infection models for enteric disease pathogens
  25. Prevalence of fibromyalgia 10 years after infection with Giardia lamblia: a controlled prospective cohort study
  26. Clinical features of gastroenteritis during a large waterborne Campylobacter outbreak in Askøy, Norway
  27. Performance and operational feasibility of two diagnostic tests for cryptosporidiosis in children (CRYPTO-POC): a clinical, prospective, diagnostic accuracy study
  28. Characteristics of hospitalized patients during a large waterborne outbreak of Campylobacter jejuni in Norway
  29. <p>Genetic Diversity of the Flavohemoprotein Gene of Giardia lamblia: Evidence for High Allelic Heterozygosity and Copy Number Variation</p>
  30. The Intriguing Interaction of Escherichia coli with the Host Environment and Innovative Strategies To Interfere with Colonization: a Summary of the 2019 E. coli and the Mucosal Immune System Meeting
  31. Bacteraemia, Malaria, and Case Fatality Among Children Hospitalized With Fever in Dar es Salaam, Tanzania
  32. Human Mucosal IgA Immune Responses against Enterotoxigenic Escherichia coli
  33. Giardiasis treatment: an update with a focus on refractory disease
  34. Comparative expression profiling in the intestine of patients with Giardia ‐induced postinfectious functional gastrointestinal disorders
  35. Plasma levels of guanylins are reduced in patients with Crohn’s disease
  36. Monocytes from neonates and adults have a similar capacity to adapt their cytokine production after previous exposure to BCG and β-glucan
  37. Whole blood preservation methods alter chemokine receptor detection in mass cytometry experiments
  38. A new human challenge model for testing heat-stable toxin-based vaccine candidates for enterotoxigenic Escherichia coli diarrhea – dose optimization, clinical outcomes, and CD4+ T cell responses
  39. Prolonged and persistent diarrhoea is not restricted to children with acute malnutrition: an observational study in Ethiopia
  40. The way forward for ETEC controlled human infection models (CHIMs)
  41. Assessment of malaria real-time PCR methods and application with focus on low-level parasitaemia
  42. Experimental Infection of Human Volunteers with the Heat-Stable Enterotoxin-Producing Enterotoxigenic Escherichia coli Strain TW11681
  43. Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia
  44. Genetic variation in metronidazole metabolism and oxidative stress pathways in clinical Giardia lamblia assemblage A and B isolates
  45. Quality of life and its association with irritable bowel syndrome and fatigue ten years after giardiasis
  46. Prolonged Duodenal Mucosal Lymphocyte Alterations in Patients With and Without Postinfectious Functional Gastrointestinal Disorders After Giardia Infection
  47. Genetic and transcriptional analysis of inflammatory bowel disease-associated pathways in patients with GUCY2C-linked familial diarrhea
  48. Proliferation of enterotoxigenic Escherichia coli strain TW11681 in stools of experimentally infected human volunteers
  49. Treatment-refractory giardiasis: challenges and solutions
  50. Longitudinal cohort study of serum antibody responses towards Giardia lamblia variant-specific surface proteins in a non-endemic area
  51. Prevalence of Irritable Bowel Syndrome and Chronic Fatigue 10 Years After Giardia Infection
  52. Transient elevation of anti-transglutaminase and anti-endomysium antibodies in Giardia infection
  53. Giardiasis: a diagnosis that should be considered regardless of the setting
  54. Genetic variation in potential Giardia vaccine candidates cyst wall protein 2 and α1-giardin
  55. Comprehensive Analysis of Prevalence, Epidemiologic Characteristics, and Clinical Characteristics of Monoinfection and Coinfection in Diarrheal Diseases in Children in Tanzania
  56. Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome
  57. A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency
  58. Long-Term Consequences of Cryptosporidium and Giardia Gastroenteritis
  59. Editorial Commentary:Giardia lamblia–Pathogen or Commensal?
  60. Excessive daytime sleepiness, sleep need and insomnia 3 years after Giardia infection: a cohort study
  61. Postinfectious and sporadic functional gastrointestinal disorders have different prevalences and rates of overlap: results from a controlled cohort study 3 years after acute giardiasis
  62. Perceived food intolerance and irritable bowel syndrome in a population 3 years after a giardiasis-outbreak: a historical cohort study
  63. Prevalence of Cryptosporidium parvum/hominis, Entamoeba histolytica and Giardia lamblia among Young Children with and without Diarrhea in Dar es Salaam, Tanzania
  64. Human Memory CD4+T Cell Immune Responses against Giardia lamblia
  65. The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection
  66. Whole genome sequencing of clinical isolates of Giardia lamblia
  67. Intestinal Microbiota And Diet in IBS: Causes, Consequences, or Epiphenomena?
  68. Hund som Giardia-kilde i Bergen i 2004 – barking up the wrong tree?
  69. Prevalence and molecular characterisation of human adenovirus in diarrhoeic children in Tanzania; a case control study
  70. Secondary transmission of Cryptosporidium parvum
  71. Irritable Bowel Syndrome and Chronic Fatigue 6 Years After Giardia Infection: A Controlled Prospective Cohort Study
  72. Genetic diversity of norovirus in hospitalised diarrhoeic children and asymptomatic controls in Dar es Salaam, Tanzania
  73. Management of chronicGiardiainfection
  74. Comparison of four methods for extracting DNA from dried blood on filter paper for PCR targeting the mitochondrial Plasmodium genome
  75. Genetic Diversity of Circulating Rotavirus Strains in Tanzania Prior to the Introduction of Vaccination
  76. En ung kvinne med langvarig diaré og slapphet
  77. Giardia-infeksjon kan gi irritabel tarm og kronisk utmattelse
  78. Praktisk anlagt oppslagsbok om tropemedisin
  79. Chronic fatigue syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course
  80. A novel, single-amplification PCR targeting mitochondrial genome highly sensitive and specific in diagnosing malaria among returned travellers in Bergen, Norway
  81. The role of arginine and arginine-metabolizing enzymes during Giardia – host cell interactions in vitro
  82. Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome
  83. The impact of atopic disease on the risk of post-infectious fatigue and irritable bowel syndrome 3 years afterGiardiainfection. A historic cohort study
  84. Human Cellular Immune Response Against Giardia lamblia 5 Years After Acute Giardiasis
  85. Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study
  86. Tolerability and effect of mesalazine in postinfectious irritable bowel syndrome
  87. Giardiasis: The Ever-Present Threat of a Neglected Disease
  88. Post epidemic giardiasis and gastrointestinal symptoms among preschool children in Bergen, Norway. A cross-sectional study
  89. Giardiasis – why do the symptoms sometimes never stop?
  90. Relative importance of abnormalities of CCK (cholecystokinin) and 5-HT (serotonin) inGiardia-induced post-infectious irritable bowel syndrome and functional dyspepsia
  91. Severity of Giardiainfection associated with post-infectious fatigue and abdominal symptoms two years after
  92. High rate of fatigue and abdominal symptoms 2 years after an outbreak of giardiasis
  93. Development of functional gastrointestinal disorders after Giardia lambliainfection
  94. Sensitivity of a Giardia antigen test in persistent giardiasis following an extensive outbreak
  95. Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway
  96. Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: A randomized open clinical trial
  97. Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection
  98. Landmine injuries in Eritrea